Faculty at School of Natural Sciences
My research interest lies in harnessing the power of bioinformatics tools to advance antiviral drug therapy. By employing molecular docking, predictive modelling, and structural bioinformatics, I aim to accelerate the discovery and development of effective interventions against viral infections. with the potential for repurposing existing drugs and identifying novel drug candidates to combat viral pathogens. By employing computational methods, I aim to expedite the discovery and development of effective interventions against viral infections.
- Molecular Docking and Virtual Screening: I specialize in utilizing molecular docking techniques and virtual screening approaches to identify potential drug candidates that target key viral proteins. By computationally simulating the interactions between viral proteins and small molecules, I can expedite the identification of promising compounds for further experimental validation.
- Structural Bioinformatics: I utilize structural bioinformatics tools to gain insights into the three-dimensional structures of viral proteins and their interactions with host factors. By understanding the molecular basis of these interactions, I aim to design inhibitors that disrupt viral replication and pathogenesis.
- Repurposing Existing Drugs: I investigate the potential of repurposing drugs for antiviral purposes. By employing bioinformatics approaches, I analyze drug databases and identify compounds with the potential to inhibit viral replication or target essential viral proteins. This strategy accelerates the drug discovery process and offers cost-effective solutions.
M. Sc Animal Genetics and Breeding - 1983
M. Phil Biotechnology - 1986
Ph.D. Plant Biochemistry - 1991
Research Associate, University of Maryland - 1994
Research Associate, Indian Institute of Science - 1998
Professor and Head, Department of Life Sciences, Shiv Nadar Institute of Eminence, Delhi-NCR 2012-2021
Professor, Department of Life Sciences, Shiv Nadar Institute of Eminence, Delhi-NCR 2021- Present
Group Leader, Panacea Biotec Ltd. New Delhi 2009-2012
Group Leader, Invitrogen Bioservices 2006-2008
Senior Research Scientist, ICGEB 1999-2006
Research Scientist (DBT), Indian Institute of Science 1995-2006
Research Associate, University of Maryland, USA 1992-1994
Recipient - Wellcome Trust Grant
- Gunjan Mishra, Vivek Ananth, Kalpesh Shelke, Deepak Sehgal, Jayaraman Classification of the Anti-Hepatitis Peptides using Hybrid-Ant Colony-Infogain Based Support Vector Machine”. Bioinformation12(1):012-014 (2016).Link:http://www.ncbi.nlm.nih.gov/pubmed/27212838
- Gunjan Mishra, Vivek Ananth, Kalpesh Shelke, Deepak Sehgal, Jayaraman Hybrid-ACO Chaos assisted Support Vector Machines for classification of Medical Datasets.” Published in Advances in Intelligent And Soft Computing (AISC) Series of Springer as SocProS 2014 Conference Proceedings. Link: http://link.springer.com/chapter /10.1007/978-81-322-2220-0_8#page-1
- Mishra, Gunjan, Deepak Sehgal, and Jayaraman K. Valadi. “Quantitative Structure-Activity Relationship study of the Anti-Hepatitis Peptides employing Random Forests and Extra-trees ” Bioinformation 13.3(2017): 60
- Hooda P, Ishtikhar M, Saraswat S, Bhatia P, Mishra D, Trivedi A, Kulandaisamy R, Aggarwal S, Munde M, Ali N, Al Asmari AF, Rauf MA, Inampudi KK, Sehgal D (2022). Biochemical and Biophysical Characterization of the Hepatitis E Virus Guanine-7-Methyltransferase. 23;27(5):1505. doi: 10.3390/molecules27051505. PMID: 35268608; PMCID: PMC8911963. IF: 5.5.
- Meenakshi Chaudhary, Vikrant Nain, Deepak Sehgal (2021). Molecular docking and dynamic simulation analysis of Hepatitis E Virus protease in complexing with the E64 inhibitor. J Biomol Struct Dyn,) org/10.1080/07391102.2021.2019124. IF: 3.392
- Meenakshi Chaudhary and Deepak Sehgal (2021). In silico identification of natural antiviral compounds as a potential inhibitor of chikungunya virus non-structural protein 3 macrodomain. J Biomol Struct Dyn (1-11) doi: 1080/07391102.2021.1960195. IF:4
- Shweta Saraswat , Meenakshi Chaudhary, Deepak Sehgal (2020).Hepatitis E Virus Cysteine Protease Has Papain Like Properties Validated by in silico Modeling and Cell-Free Inhibition Assays Front Cell Infect Microbiol .23;9:478. IF: 293
- Kumar M, Hooda P, Khanna M, Patel U, Sehgal D (2020). Development of BacMam Induced Hepatitis E Virus Replication Model in Hepatoma Cells to Study the Polyprotein Processing. Front Microbiol. 18; 11:1347. doi: 3389/fmicb.2020.01347. PMID: 32625196; PMCID: PMC7315041. IF: 5.6.
- Modak, , Mehta, S., Sehgal, D., & Valadi, J. (2019). Application of Support Vector Machines in Viral Biology. Global Virology III: Virology in the 21st Century, 361–403. https://doi.org/10.1007/978-3-030-29022-1_12
- Rajkumar Kulandaisamy,Tushar Kushwaha Manoj Kumar,Saroj Kumar, Aparoy Mohan B Appaiahgari, Madhumohan R Katika, Krishna Kishore Inampudi, (2022). Computational and Structural Biotechnology Repurposing of FDA approved drugs against SARS-CoV-2 Papain-Like protease by using computational, biochemical, and in vitro Frontiers in Microbiology ;1; IF: 5.5.
- Hooda, P.; Chaudhary, M.; Parvez, M.K.; Sinha, N.; Sehgal, D. Inhibition of Hepatitis E Virus Replication by Novel Inhibitor Targeting Methyltransferase. Viruses 2022, 14, 1778. IF 5.04
Development of an In Vitro System for HEV Propagation to study Polyprotein processing and experimental infection in Murine model - 58 Lakhs awarded by DST
Structural characterization and inhibitor development for HEV-Methyltransferase - 45 Lakhs awarded by DBT
Complement regulatory proteins and innate immune response in Influenza A Virus infection. (In collaboration) - 48 Lakhs awarded by DBT
Structure-based design of nanobody inhibitors against EGFR: A protein engineering approach to develop novel therapeutics for lung cancer (In collaboration) - 45 Lakhs awarded by ICMR